Undisclosed Immunotherapy
Triple-Negative Breast Cancer (TNBC)
Key Facts
About Apheon Bioscience
Apheon Bioscience is a private, preclinical biotech founded in 2020, headquartered in Cambridge, Massachusetts. The company is developing targeted immunotherapies for oncology and women's health indications, including Triple-Negative Breast Cancer (TNBC), Leiomyosarcoma, and Endometriosis, utilizing its proprietary ApheGenixID™ antigen discovery and antibody engineering platform. Its strategy combines internal asset development with a fee-for-service and partnership model, offering precision DNA cloning and antibody discovery services to other biopharma entities. Apheon is currently pre-revenue and is led by a team with deep expertise in molecular biology and immunology, seeking strategic partnerships and investment to advance its pipeline.
View full company profileAbout Apheon Bioscience
Apheon Bioscience is a private, preclinical biotech founded in 2020, headquartered in Cambridge, Massachusetts. The company is developing targeted immunotherapies for oncology and women's health indications, including Triple-Negative Breast Cancer (TNBC), Leiomyosarcoma, and Endometriosis, utilizing its proprietary ApheGenixID™ antigen discovery and antibody engineering platform. Its strategy combines internal asset development with a fee-for-service and partnership model, offering precision DNA cloning and antibody discovery services to other biopharma entities. Apheon is currently pre-revenue and is led by a team with deep expertise in molecular biology and immunology, seeking strategic partnerships and investment to advance its pipeline.
View full company profileAbout Apheon Bioscience
Apheon Bioscience is a private, preclinical biotech founded in 2020, headquartered in Cambridge, Massachusetts. The company is developing targeted immunotherapies for oncology and women's health indications, including Triple-Negative Breast Cancer (TNBC), Leiomyosarcoma, and Endometriosis, utilizing its proprietary ApheGenixID™ antigen discovery and antibody engineering platform. Its strategy combines internal asset development with a fee-for-service and partnership model, offering precision DNA cloning and antibody discovery services to other biopharma entities. Apheon is currently pre-revenue and is led by a team with deep expertise in molecular biology and immunology, seeking strategic partnerships and investment to advance its pipeline.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer (TNBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| Nadunolimab (CAN04) | Cantargia | Phase II |
| Breast Cancer Vaccine | Anixa Biosciences | Phase 1b |